[PubMed] [Google Scholar] 2. Scholar] 3. Demyttenaere K., Enzlin P., Dewe W., et al. Compliance with antidepressants in a primary care setting I: beyond lack of efficacy and adverse events. . 2001;62(suppl 22):30C33. [PubMed] [Google Scholar] 4. Wisniewski SR., Rush AJ., Balasubramani GK., Trivedi MH., Nierenberg AA. Self-rated global CRT0044876 measure of the frequency, intensity and burden of side effects. . 2006;12:71C79. [PubMed] [Google Scholar] 5. Clyde DJ. SAFTEE: data system for side effect assessment scale. . 1986;22:287. [PubMed] [Google Scholar] 6. Nelson JC., Jatlow P., Quinlan DM. Subjective side effects during desipramine treatment. . 1984;41:55C59. [PubMed] [Google Scholar] 7. Rush AJ. Giles DE. Schlesser MA. Fulton CL. Weissenburger J. Burns C. The Inventory for Depressive Symptomatology (IDS): preliminary findings. . 1986;18:65C87. [PubMed] [Google Scholar] 8. Lin EHB., Von Korff M., Katon W., et al. The role of the primary care physician in patients’ adherence to antidepressant therapy. . 1995;33:67C74. [PubMed] [Google Scholar] 9. Papakostas Gl. Limitations of contemporary antidepressants:tolerability. . 2007;68(suppl 10):11C17. [PubMed] [Google Scholar] 10. Bull SA., Hunkeler EM., Lee JY., et al. Discontinuation or switching selective serotonin-reuptake inhibitors. CRT0044876 . 2002;36:578C584. [PubMed] [Google Scholar] 11. Hunter AM. Cook IA. Leuchter AF. The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder. [122 refs] . 2007;30:105C124. Review. [PubMed] [Google Scholar] 12. losifescu DV., Renshaw PF., Lyoo IK., et al. Brain white-matter hyperintensites and treatment outcome in major depressive disorder. . 2006;188:180C185. [PubMed] [Google Scholar] 13. Trindade D., Menon D., Topfer L., Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. . 1998;159:1245C1252. [PMC free article] [PubMed] [Google Scholar] 14. Papakostas Gl., Nutt DJ., Hallett LA., et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. . 2006;60:1350C1355. [PubMed] [Google Scholar] 15. Papakostas Gl., Nelson JC., Kasper S., Moller HJ. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. . 2008;18:122C127. [PubMed] [Google Scholar] 16. Baldwin DS., Hawley CJ., Abed RT., et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. . 1996;58(suppl 2):46C52. [PubMed] [Google Scholar] 17. Feiger A., Kiev A., Shrivastava RK., et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. . 1996;57(suppl 2):53C62. [PubMed] [Google Scholar] 18. Berlanga C., Arechavaleta B., Heinze G., et al. A double-blind comparison of nefazodone and fluoxetine in the treatment of depressed outpatients. . 1997;20:1C8. [Google Scholar] 19. Montgomery SA., Huusom AK., Bothmer J. A randomized study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. . 2004;50:57C64. [PubMed] [Google Scholar] 20. Bielski RJ., Ventura D., Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. . 2004;65:1190C1196. [PubMed] [Google Scholar] 21. Schatzberg A., Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. . 2006;14:361C370. [PubMed] [Google.2000;10:305C314. . 2002;288:1403C1409. [PubMed] [Google Scholar] 3. Demyttenaere K., Enzlin P., Dewe W., et al. Compliance with antidepressants in a primary care setting I: beyond lack of efficacy and adverse events. . 2001;62(suppl 22):30C33. [PubMed] [Google Scholar] 4. Wisniewski SR., Rush AJ., Balasubramani GK., Trivedi MH., Nierenberg AA. Self-rated global measure of the frequency, intensity and burden of side effects. . 2006;12:71C79. [PubMed] [Google Scholar] 5. Clyde DJ. SAFTEE: data system for side effect assessment scale. . 1986;22:287. [PubMed] [Google Scholar] 6. Nelson JC., Jatlow P., Quinlan DM. Subjective side effects during desipramine treatment. . 1984;41:55C59. [PubMed] [Google Scholar] 7. Rush AJ. Giles DE. Schlesser MA. Fulton CL. Weissenburger J. Burns C. The Inventory for Depressive Symptomatology (IDS): preliminary findings. . 1986;18:65C87. [PubMed] [Google Scholar] 8. Lin EHB., Von Korff M., Katon W., et al. The role of the primary care physician in patients’ adherence to antidepressant therapy. . 1995;33:67C74. [PubMed] [Google Scholar] 9. Papakostas Gl. Limitations of contemporary antidepressants:tolerability. . 2007;68(suppl 10):11C17. [PubMed] [Google Scholar] 10. Bull SA., Hunkeler EM., Lee JY., et al. Discontinuation or switching selective serotonin-reuptake inhibitors. . 2002;36:578C584. [PubMed] [Google Scholar] 11. Hunter AM. Cook IA. Leuchter AF. The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder. [122 refs] . 2007;30:105C124. Review. [PubMed] [Google Scholar] 12. losifescu DV., Renshaw PF., Lyoo IK., et al. Brain white-matter hyperintensites and treatment outcome in major depressive disorder. . 2006;188:180C185. [PubMed] [Google Scholar] 13. Trindade Rabbit Polyclonal to HSP90A D., Menon D., Topfer L., Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. . 1998;159:1245C1252. [PMC free article] [PubMed] [Google Scholar] 14. Papakostas Gl., Nutt DJ., Hallett LA., et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. . 2006;60:1350C1355. [PubMed] [Google Scholar] 15. Papakostas Gl., Nelson JC., Kasper S., Moller HJ. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. . 2008;18:122C127. [PubMed] [Google Scholar] 16. Baldwin DS., Hawley CJ., Abed RT., et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. . 1996;58(suppl 2):46C52. [PubMed] [Google Scholar] 17. Feiger A., Kiev A., Shrivastava RK., et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. . 1996;57(suppl 2):53C62. [PubMed] [Google Scholar] 18. Berlanga C., Arechavaleta B., Heinze G., et al. A double-blind comparison of nefazodone and fluoxetine in the treatment of depressed outpatients. . 1997;20:1C8. [Google Scholar] 19. Montgomery SA., Huusom AK., Bothmer J. A randomized study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. . 2004;50:57C64. [PubMed] [Google Scholar] 20. Bielski RJ., Ventura D., Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of main depressive disorder. . 2004;65:1190C1196. [PubMed] [Google Scholar] 21. Schatzberg A., Roose S. A double-blind, placebo-controlled research of venlafaxine and fluoxetine in geriatric outpatients with main melancholy. . 2006;14:361C370. [PubMed] [Google Scholar] 22. Nelson JC., Prtichett YL., Martynov O., et al. The protection and tolerability of.. Furthermore, we address the most frequent side effects such as for example intimate dysfunction, gastrointestinal complications, sleep disruption, apathy, and exhaustion, and offer approaches for management that might help individuals achieve ideal response to pharmacotherapy. 2004;65:959C965. [PubMed] [Google Scholar] 2. Bull SA., Hu XU., Hunkeler EM., et al. Discontinuation useful and switching of antidepressants: impact of patient-physician conversation. . 2002;288:1403C1409. [PubMed] [Google Scholar] 3. Demyttenaere K., Enzlin P., Dewe W., et al. Conformity with antidepressants inside a major care placing I: beyond insufficient effectiveness and adverse occasions. . 2001;62(suppl 22):30C33. [PubMed] [Google Scholar] 4. Wisniewski SR., Hurry AJ., Balasubramani GK., Trivedi MH., Nierenberg AA. Self-rated global way of measuring the frequency, strength and burden of unwanted effects. . 2006;12:71C79. [PubMed] [Google Scholar] 5. Clyde DJ. SAFTEE: data program for side-effect assessment size. . 1986;22:287. [PubMed] [Google Scholar] 6. Nelson JC., Jatlow P., Quinlan DM. Subjective unwanted effects during desipramine treatment. . 1984;41:55C59. [PubMed] [Google Scholar] 7. Hurry AJ. Giles DE. Schlesser MA. Fulton CL. Weissenburger J. Melts away C. The Inventory for Depressive Symptomatology (IDS): initial results. . 1986;18:65C87. [PubMed] [Google Scholar] 8. Lin EHB., Von Korff M., Katon W., et al. The part of the principal care doctor in individuals’ adherence to antidepressant therapy. . 1995;33:67C74. [PubMed] [Google Scholar] 9. Papakostas Gl. Restrictions of modern antidepressants:tolerability. . 2007;68(suppl 10):11C17. [PubMed] [Google Scholar] 10. Bull SA., Hunkeler EM., Lee JY., et al. Discontinuation or switching selective serotonin-reuptake inhibitors. . 2002;36:578C584. [PubMed] [Google Scholar] 11. Hunter AM. Make IA. Leuchter AF. The guarantee from the quantitative electroencephalogram like a predictor of antidepressant treatment results in main depressive disorder. [122 refs] . 2007;30:105C124. Review. [PubMed] [Google Scholar] 12. losifescu DV., Renshaw PF., Lyoo IK., et al. Mind white-matter hyperintensites and treatment result in main depressive disorder. . 2006;188:180C185. [PubMed] [Google Scholar] 13. Trindade D., Menon D., Topfer L., Coloma C. Undesireable effects connected with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. . 1998;159:1245C1252. [PMC free of charge content] [PubMed] [Google Scholar] 14. Papakostas Gl., Nutt CRT0044876 DJ., Hallett LA., et al. Quality of sleepiness and exhaustion in main depressive disorder: an evaluation of bupropion as well as the selective serotonin reuptake inhibitors. . 2006;60:1350C1355. [PubMed] [Google Scholar] 15. Papakostas Gl., Nelson JC., Kasper S., Moller HJ. A meta-analysis of medical trials evaluating reboxetine, a norepinephrine reuptake inhibitor with selective serotonin reuptake inhibitors for the treating main depressive disorder. . 2008;18:122C127. [PubMed] [Google Scholar] 16. Baldwin DS., Hawley CJ., Abed RT., et al. A multicenter double-blind assessment of nefazodone and paroxetine in the treating outpatients with moderate-to-severe melancholy. . 1996;58(suppl 2):46C52. [PubMed] [Google Scholar] 17. Feiger A., Kiev A., Shrivastava RK., et al. Nefazodone versus sertraline in outpatients with main depression: concentrate on effectiveness, tolerability, and results on intimate function and fulfillment. . 1996;57(suppl 2):53C62. [PubMed] [Google Scholar] 18. Berlanga C., Arechavaleta B., Heinze G., et al. A double-blind assessment of nefazodone and fluoxetine in the treating frustrated outpatients. . 1997;20:1C8. [Google Scholar] 19. Montgomery SA., Huusom AK., Bothmer J. A randomized research evaluating escitalopram with venlafaxine XR in major care individuals with main depressive disorder. . 2004;50:57C64. [PubMed] [Google Scholar] 20. Bielski RJ., Ventura D., Chang CC. A double-blind assessment of escitalopram and venlafaxine prolonged release in the treating main depressive disorder. . 2004;65:1190C1196. [PubMed] [Google Scholar] 21. Schatzberg A., Roose S. A double-blind, placebo-controlled research of venlafaxine and fluoxetine in geriatric outpatients with main melancholy. . 2006;14:361C370. [PubMed] [Google Scholar] 22. Nelson JC., Prtichett YL., Martynov O., et al. The protection and tolerability of duloxetine weighed against paroxetine and placebo: a pooled evaluation of 4 medical tests. . 2006;8:212C219. [PMC free of charge content] [PubMed] [Google Scholar] 23. Goldstien DJ., Mallinckrodt C., Lu Y., et al. Duloxetine in the treating main depressive disorder: a double-blind, placebo-controlled trial. . 2002;63:225C231. [PubMed] [Google Scholar] 24. Papakostas Gl., Fava M. A meta-analysis of medical trials evaluating moclobemide with selective serotonin reuptake inhibitors for the treating main depressive disorder. . 2006;51:783C790. [PubMed] [Google Scholar] 25. Papakostas Gl., Homberger CH., Fava M. A meta-analysis of medical trials evaluating mirtazapine having a selective serotonin reuptake inhibitor for the treating main depressive disorder. . 1991;52:294C299. [PubMed] [Google Scholar] 27. Zajecka J. Approaches for the treating antidepressant-related intimate dysfunction. . 2001;62(suppl 3):35C43. [PubMed] [Google Scholar] 28. Montejo-Gonzalez AL., Llorca G., et al. SSRI-induced intimate dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamlne inside a potential, multicenter,.losifescu DV., Renshaw PF., Lyoo IK., et al. depressive symptoms, discontinuation results, and general medical complications. Furthermore, we address the most frequent side effects such as for example intimate dysfunction, gastrointestinal complications, sleep disruption, apathy, and exhaustion, and offer approaches for management that might help individuals achieve ideal response to pharmacotherapy. 2004;65:959C965. [PubMed] [Google Scholar] 2. Bull SA., Hu XU., Hunkeler EM., et al. Discontinuation useful and switching of antidepressants: impact of patient-physician conversation. . 2002;288:1403C1409. [PubMed] [Google Scholar] 3. Demyttenaere K., Enzlin P., Dewe W., et al. Conformity with antidepressants inside a major care placing I: beyond insufficient effectiveness and adverse occasions. . 2001;62(suppl 22):30C33. [PubMed] [Google Scholar] 4. Wisniewski SR., Hurry AJ., Balasubramani GK., Trivedi MH., Nierenberg AA. Self-rated global way of measuring the frequency, strength and burden of unwanted effects. . 2006;12:71C79. [PubMed] [Google Scholar] 5. Clyde DJ. SAFTEE: data program for side-effect assessment size. . 1986;22:287. [PubMed] [Google Scholar] 6. Nelson JC., Jatlow P., Quinlan DM. Subjective unwanted effects during desipramine treatment. . 1984;41:55C59. [PubMed] [Google Scholar] 7. Hurry AJ. Giles DE. Schlesser MA. Fulton CL. Weissenburger J. Melts away C. The Inventory for Depressive Symptomatology (IDS): initial results. . 1986;18:65C87. [PubMed] [Google Scholar] 8. Lin EHB., Von Korff M., Katon W., et al. The part of the principal care doctor in individuals’ adherence to antidepressant therapy. . 1995;33:67C74. [PubMed] [Google Scholar] 9. Papakostas Gl. Restrictions of modern antidepressants:tolerability. . 2007;68(suppl 10):11C17. [PubMed] [Google Scholar] 10. Bull SA., Hunkeler EM., Lee JY., et al. Discontinuation or switching selective serotonin-reuptake inhibitors. . 2002;36:578C584. [PubMed] [Google Scholar] 11. Hunter AM. Make IA. Leuchter AF. The guarantee from the quantitative electroencephalogram like a predictor of antidepressant treatment results in main depressive disorder. [122 refs] . 2007;30:105C124. Review. [PubMed] [Google Scholar] 12. losifescu DV., Renshaw PF., Lyoo IK., et al. Mind white-matter hyperintensites and treatment result in main depressive disorder. . 2006;188:180C185. [PubMed] [Google Scholar] 13. Trindade D., Menon D., Topfer L., Coloma C. Undesireable effects connected with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. . 1998;159:1245C1252. [PMC free of charge content] [PubMed] [Google Scholar] 14. Papakostas Gl., Nutt DJ., Hallett LA., et al. Quality of sleepiness and exhaustion in main depressive disorder: an evaluation of bupropion as well as the selective serotonin reuptake inhibitors. . 2006;60:1350C1355. [PubMed] [Google Scholar] 15. Papakostas Gl., Nelson JC., Kasper S., Moller HJ. A meta-analysis of medical trials evaluating reboxetine, a norepinephrine reuptake inhibitor with selective serotonin reuptake inhibitors for the treating main depressive disorder. . 2008;18:122C127. [PubMed] [Google Scholar] 16. Baldwin DS., Hawley CJ., Abed RT., et al. A multicenter double-blind assessment of nefazodone and paroxetine in the treating outpatients with moderate-to-severe melancholy. . 1996;58(suppl 2):46C52. [PubMed] [Google Scholar] 17. Feiger A., Kiev A., Shrivastava RK., et al. Nefazodone versus sertraline in outpatients with main depression: concentrate on effectiveness, tolerability, and results on intimate function and fulfillment. . 1996;57(suppl 2):53C62. [PubMed] [Google Scholar] 18. Berlanga C., Arechavaleta B., Heinze G., et al. A double-blind assessment of nefazodone and fluoxetine in the treating frustrated outpatients. . 1997;20:1C8. [Google Scholar] 19. Montgomery SA., Huusom AK., Bothmer J. A randomized research evaluating escitalopram with venlafaxine XR in major care individuals with main depressive disorder. . 2004;50:57C64. [PubMed] [Google Scholar] 20. Bielski RJ., Ventura D., Chang CC. A double-blind assessment of escitalopram and venlafaxine prolonged release in the treating main depressive disorder. . 2004;65:1190C1196. [PubMed] [Google Scholar] 21. Schatzberg A., Roose S. A double-blind, placebo-controlled research of venlafaxine and fluoxetine in geriatric outpatients with main melancholy. . 2006;14:361C370. [PubMed] [Google Scholar] 22. Nelson JC., Prtichett YL., Martynov O., et al. The protection and tolerability of duloxetine weighed against paroxetine and placebo: a pooled evaluation of 4 medical tests. . 2006;8:212C219. [PMC free of charge content] [PubMed] [Google Scholar] 23. Goldstien DJ., Mallinckrodt C., Lu Y., et al. Duloxetine in the treating main depressive disorder: a double-blind, placebo-controlled trial. . 2002;63:225C231. [PubMed] [Google Scholar] 24. Papakostas Gl., Fava M. A meta-analysis of medical trials evaluating moclobemide with selective serotonin reuptake inhibitors for the treating main depressive disorder. . 2006;51:783C790. [PubMed] [Google Scholar] 25. Papakostas Gl., Homberger CH., Fava M. A meta-analysis of medical trials evaluating mirtazapine having a selective serotonin reuptake inhibitor for the treating main depressive disorder. . 1991;52:294C299. [PubMed] [Google Scholar] 27. Zajecka J. Approaches for the treating antidepressant-related intimate dysfunction. . 2001;62(suppl 3):35C43. [PubMed] [Google Scholar] 28. Montejo-Gonzalez AL., Llorca G., et al. SSRI-induced intimate dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamlne.